Business Description
Nasus Pharma Ltd
ISIN : IL0012181553
Total Employee Number:
7Description
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 36.32 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -26.3 | |||||
3-Year EPS without NRI Growth Rate | -27.3 | |||||
3-Year FCF Growth Rate | -53 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.04 | |||||
9-Day RSI | 42.71 | |||||
14-Day RSI | 45.65 | |||||
3-1 Month Momentum % | -4.06 | |||||
6-1 Month Momentum % | -55.34 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.24 | |||||
Quick Ratio | 2.24 | |||||
Cash Ratio | 1.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | -19.79 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -276.23 | |||||
ROIC % | -207.74 | |||||
3-Year ROIIC % | 247.58 | |||||
ROC (Joel Greenblatt) % | -3291.28 | |||||
Moat Score | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 9.39 | |||||
Price-to-Tangible-Book | 9.39 | |||||
EV-to-EBIT | -6.1 | |||||
EV-to-EBITDA | -6.1 | |||||
EV-to-FCF | -6.08 | |||||
| Price-to-Net-Current-Asset-Value | 10.03 | |||||
| Price-to-Net-Cash | 12.65 | |||||
Earnings Yield (Greenblatt) % | -16.39 | |||||
FCF Yield % | -14.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:NSRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nasus Pharma Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.649 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 45.65 | ||
| 14-Day ATR ($) | 0.21339 | ||
| 20-Day SMA ($) | 3.20456 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 1.98 - 9.9899 | ||
| Shares Outstanding (Mil) | 11.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nasus Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nasus Pharma Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-30 | In 131 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 40 days | ||
| First quarter earnings results for 2026 | 2026-07-21 | 3.01 (+1.69%) | ||
| Life Sciences Virtual Investor Forum | 2026-06-24 11:00 | 3.30 (+6.11%) | ||
| Annual report for 2025 | 2026-03-25 | 2.49 (+1.22%) | ||
| Nasus Pharma Phase 2 Repeated Dose Clinical Study of NS002 Intranasal Epinepherine | 2026-03-16 08:00 | 5.00 (+0.00%) | ||
| Virtual Investor Conferences | 2026-03-11 12:30 | 4.62 (+6.45%) |
Show
Entries
Nasus Pharma Ltd Frequently Asked Questions
What is Nasus Pharma Ltd(NSRX)'s stock price today?
The current price of NSRX is $2.91. The 52 week high of NSRX is $9.99 and 52 week low is $1.98.
When is next earnings date of Nasus Pharma Ltd(NSRX)?
The next earnings date of Nasus Pharma Ltd(NSRX) is 2026-08-31 Est..
Does Nasus Pharma Ltd(NSRX) pay dividends? If so, how much?
Nasus Pharma Ltd(NSRX) does not pay dividend.
Guru Commentaries on AMEX:NSRX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Nasus Pharma Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers